D
Dyne Therapeutics, Inc.
DYN
$12.40
$0.161.31%
D
Sell
12/4/2023Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D- from E+ on 12/4/2023 due to an increase in the volatility index.
Dyne Therapeutics, Inc. (DYN) was upgraded to D- from E+ on 12/4/2023 due to an increase in the volatility index.
E
Sell
11/16/2023Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D- on 11/16/2023 due to a decline in the total return index, solvency index and valuation index. Debt to equity increased from 0.02 to 0.03, and the quick ratio declined from 10.27 to 5.32.
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D- on 11/16/2023 due to a decline in the total return index, solvency index and valuation index. Debt to equity increased from 0.02 to 0.03, and the quick ratio declined from 10.27 to 5.32.
D
Sell
8/4/2023Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D- from E+ on 8/4/2023 due to an increase in the volatility index, solvency index and total return index.
Dyne Therapeutics, Inc. (DYN) was upgraded to D- from E+ on 8/4/2023 due to an increase in the volatility index, solvency index and total return index.
E
Sell
8/1/2023Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D- on 8/1/2023 due to a decline in the total return index, volatility index and growth index.
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D- on 8/1/2023 due to a decline in the total return index, volatility index and growth index.
D
Sell
7/13/2023Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D- from E+ on 7/13/2023 due to an increase in the volatility index and total return index.
Dyne Therapeutics, Inc. (DYN) was upgraded to D- from E+ on 7/13/2023 due to an increase in the volatility index and total return index.
E
Sell
6/26/2023Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D- on 6/26/2023 due to a decline in the volatility index and total return index.
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D- on 6/26/2023 due to a decline in the volatility index and total return index.
D
Sell
6/6/2023Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D- from E+ on 6/6/2023 due to an increase in the volatility index and valuation index.
Dyne Therapeutics, Inc. (DYN) was upgraded to D- from E+ on 6/6/2023 due to an increase in the volatility index and valuation index.
E
Sell
5/18/2023Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D- on 5/18/2023 due to a decline in the volatility index, growth index and total return index. Operating cash flow declined 60.69% from -$29.19M to -$46.91M, EBIT declined 13.25% from -$40.15M to -$45.46M, and earnings per share declined from -$0.7351 to -$0.7845.
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D- on 5/18/2023 due to a decline in the volatility index, growth index and total return index. Operating cash flow declined 60.69% from -$29.19M to -$46.91M, EBIT declined 13.25% from -$40.15M to -$45.46M, and earnings per share declined from -$0.7351 to -$0.7845.
D
Sell
3/14/2023Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/23/2023Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
D
Sell
2/8/2023Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and growth index. Operating cash flow declined 38.49% from -$30.91M to -$42.81M, and the quick ratio declined from 11.39 to 10.64.
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and growth index. Operating cash flow declined 38.49% from -$30.91M to -$42.81M, and the quick ratio declined from 11.39 to 10.64.
D
Sell
9/1/2022Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 9/1/2022 due to an increase in the total return index and volatility index.
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 9/1/2022 due to an increase in the total return index and volatility index.
D
Sell
8/8/2022Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 8/8/2022 due to a noticeable decline in the growth index and solvency index. Debt to equity increased from 0.01 to 0.02, EBIT declined 47.43% from -$35.78M to -$52.76M, and earnings per share declined from -$0.6896 to -$1.0121.
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 8/8/2022 due to a noticeable decline in the growth index and solvency index. Debt to equity increased from 0.01 to 0.02, EBIT declined 47.43% from -$35.78M to -$52.76M, and earnings per share declined from -$0.6896 to -$1.0121.
D
Sell
8/4/2022Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index and total return index.
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index and total return index.
D
Sell
7/20/2022Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index and valuation index.
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index and valuation index.
D
Sell
6/29/2022Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 6/29/2022 due to an increase in the volatility index.
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 6/29/2022 due to an increase in the volatility index.
D
Sell
6/13/2022Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index and total return index.
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/16/2022Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Dyne Therapeutics, Inc. (DYN) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 05/04/2022.
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 05/04/2022.
D
Sell
5/3/2022Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D- from E+ on 5/3/2022 due to a large increase in the growth index, total return index and valuation index. Earnings per share increased from -$1.0047 to -$0.6896, and EBIT increased 31.13% from -$51.96M to -$35.78M.
Dyne Therapeutics, Inc. (DYN) was upgraded to D- from E+ on 5/3/2022 due to a large increase in the growth index, total return index and valuation index. Earnings per share increased from -$1.0047 to -$0.6896, and EBIT increased 31.13% from -$51.96M to -$35.78M.
E
Sell
4/20/2022Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, growth index and solvency index. The quick ratio declined from 17.45 to 13.11, EBIT declined 21.5% from -$42.77M to -$51.96M, and earnings per share declined from -$0.8297 to -$1.0047.
Dyne Therapeutics, Inc. (DYN) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, growth index and solvency index. The quick ratio declined from 17.45 to 13.11, EBIT declined 21.5% from -$42.77M to -$51.96M, and earnings per share declined from -$0.8297 to -$1.0047.
D
Sell
1/12/2022Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 1/12/2022 due to a decline in the volatility index and total return index.
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 1/12/2022 due to a decline in the volatility index and total return index.
D
Sell
12/23/2021Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 12/23/2021 due to an increase in the total return index, volatility index and valuation index.
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 12/23/2021 due to an increase in the total return index, volatility index and valuation index.
D
Sell
12/8/2021Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 12/8/2021 due to a decline in the total return index and volatility index.
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 12/8/2021 due to a decline in the total return index and volatility index.
D
Sell
11/23/2021Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 11/23/2021.
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.5849 to -$0.8297, EBIT declined 41.77% from -$30.17M to -$42.77M, and the quick ratio declined from 29.94 to 17.45.
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.5849 to -$0.8297, EBIT declined 41.77% from -$30.17M to -$42.77M, and the quick ratio declined from 29.94 to 17.45.
D
Sell
5/7/2021Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 5/7/2021 due to a major increase in the growth index and solvency index. Earnings per share increased from -$0.6327 to -$0.5047, the quick ratio increased from 31.49 to 35.92, and EBIT increased 12.12% from -$28.6M to -$25.13M.
Dyne Therapeutics, Inc. (DYN) was upgraded to D from D- on 5/7/2021 due to a major increase in the growth index and solvency index. Earnings per share increased from -$0.6327 to -$0.5047, the quick ratio increased from 31.49 to 35.92, and EBIT increased 12.12% from -$28.6M to -$25.13M.
D
Sell
3/5/2021Downgrade
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 3/5/2021 due to a substantial decline in the efficiency index, growth index and volatility index. EBIT declined 111.54% from -$13.52M to -$28.6M, net income declined 105.81% from -$13.92M to -$28.65M, and operating cash flow declined 68.75% from -$11.87M to -$20.04M.
Dyne Therapeutics, Inc. (DYN) was downgraded to D- from D on 3/5/2021 due to a substantial decline in the efficiency index, growth index and volatility index. EBIT declined 111.54% from -$13.52M to -$28.6M, net income declined 105.81% from -$13.92M to -$28.65M, and operating cash flow declined 68.75% from -$11.87M to -$20.04M.
D
Sell
12/23/2020Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to D from E on 12/23/2020 due to an increase in the volatility index.
Dyne Therapeutics, Inc. (DYN) was upgraded to D from E on 12/23/2020 due to an increase in the volatility index.
E
Sell
12/22/2020Upgraded
Dyne Therapeutics, Inc. (DYN) was upgraded to E from E- on 12/22/2020 due to an increase in the volatility index and total return index.
Dyne Therapeutics, Inc. (DYN) was upgraded to E from E- on 12/22/2020 due to an increase in the volatility index and total return index.
E
Sell
12/10/2020None
Dyne Therapeutics, Inc. (DYN) was downgraded to E- from U on 12/10/2020.
Dyne Therapeutics, Inc. (DYN) was downgraded to E- from U on 12/10/2020.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
